Sickle Cell Disease
HAEMOLIFE™ Biotherapeutic Programme
Overview
Sickle cell disease is an inherited haemoglobin disorder characterised by abnormal red blood cell morphology and recurrent vaso-occlusive complications. Standard medical care focuses primarily on crisis management and long-term complication reduction.
UGO Genetics UK has developed HAEMOLIFE™, a structured 15-day oral biotherapeutic programme designed to address underlying biological mechanisms associated with sickle cell disease. The programme is delivered within a research-driven clinical framework and is non-surgical.
Scientific Foundation
HAEMOLIFE™ is based on proprietary work involving plant-derived mesenchymal phyto stem cell aggregates. These cellular derivatives are of plant origin and do not involve human or animal embryonic tissue.
The therapeutic model focuses on modulation of pathways associated with:
- Red blood cell structural integrity
- Haemoglobin polymerisation behaviour
- Inflammatory cascade regulation
- Systemic cellular adaptation
Clinical monitoring has indicated measurable changes in haematological parameters in selected individuals following completion of the 15-day protocol.
This work contributes to expanding scientific understanding of advanced approaches in the treatment of sickle cell disease.
Understanding the Condition
- HbSS
- HbSC
- HbS beta-thalassaemia
Programme Structure
Pre-Treatment Evaluation
Baseline investigations are conducted prior to initiation:
- Haemoglobin electrophoresis
- Full blood count
These values serve as objective reference points for post-treatment comparison.
Post-Treatment Monitoring
Laboratory reassessment is typically conducted at:
- 1 month
- 9 months
This allows longitudinal evaluation of haematological stability.
Dosage Protocol
Dosing is stratified by age category:
| Age Category | Dosage | Frequency |
|---|---|---|
| Ages 2–11 years | 300 ml | Three times daily, for 15 days |
| Ages 12 years and above | 600 ml | Three times daily, for 15 days |
All administration occurs under structured clinical supervision.
Clinical Observations
Within monitored cohorts, follow-up assessment has been documented:
- Sustained stabilisation of haemoglobin electrophoresis profiles in selected individuals
- Reduced incidence of vaso-occlusive episodes in certain cases
- Improved functional tolerance reported by patients following programme completion
- No acute treatment-related incompatibility observed during monitored periods
Therapeutic Positioning
HAEMOLIFE™ is designed to function as a primary biotherapeutic intervention within its defined programme structure.
In monitored settings, patients completing the full protocol have demonstrated continued clinical stability beyond the treatment period. While individual outcomes differ, the programme is structured to operate independently within its clinical model.
It should not be interpreted as a universal cure, and ongoing specialist evaluation remains recommended.
Important Information
- HAEMOLIFE™ is delivered within a research-oriented clinical framework.
- Suitability is determined following individual assessment.
Continuity of specialist haematology care is advised.
Medical Disclaimer
This content is provided for informational purposes only and does not replace professional medical advice. Decisions for treatment for sickle cell disease should be made in consultation with a qualified healthcare professional.